Under the category of the OTC/Nutraceutical products are listed the products which are sold without prescription. Members of Farmavita.net are invited to publish their out-license offers in this Category.

Description

There is on-going development of  generic EU CTD Dossier of  Irbesartan, tablets, 75-150-300 mg.

Dossier should be available in October 2006.

Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

Hypertension

Irbesartan is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Nephropathy in Type 2 Diabetic Patients

Irbesartan is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. In this population, Irbesartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation)

More details at http://www.rxlist.com/cgi/generic/irbesart.htm 

More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 34

Advertiser details

Contact Advertiser

Add comment

 
 

Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favourites

Sorry, you need to register or login first.

Advert search

Recent adverts

OUT-LICENSING HYBRID DOSSIER OF ALIMEMAZINE...
64 Views
 Company portfolio: Manufacturing over 100...
323 Views
Objective: To enter into EU domain grabbing a...
119 Views
OUT-LICENSING DOSSIER OF ALIMEMAZINE TABLETS OF...
157 Views
Please contact me.  if you need...
600 Views
Unique supplement products is needed for...
424 Views